1 Coleman R E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 2006, 12: 6243s–6249s？？
[2]
3 Guise T A, Mohammad K S, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res, 2006, 12: 6213s–6216s？？
[3]
4 Ibrahim T, Flamini E, Mercatali L, et al. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer, 2010, 116: 1406– 1418？？
[4]
5 Roato I, D’Amelio P, Gorassini E, et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE, 2008, 3: e3627？？
[5]
7 Shailendra K. Lanthanum and its rapidly emerging role as an anti-carcinogenic agent. J Cell Biochem, 2009, 106: 193？？
9 Wang P, Zou X M, Huang J, et al. Gadolinium inhibits prostate cancer PC3 cell migration and suppresses osteoclast differentiation in vitro. Cell Biol Int, 2011, 35: 1159–1167？？
[8]
10 Boyle W J, Simonet W S, Lacey D L. Osteoclast differentiation and activation. Nature, 2003, 423: 337–342？？
[9]
13 Liu H, Liu Y, Viggeswarapu M, et al. Activation of c-Jun NH(2)-terminal kinase 1 increases cellular responsiveness to BMP-2 and decreases binding of inhibitory Smad6 to the type I BMP receptor. J Bone Miner Res, 2011, 26: 1122–1132？？
[10]
14 Lacey D L, Timms E, Tan H L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93: 165–176？？
[11]
2 Casimiro S, Guise T A, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrin, 2009, 310: 71–81？？
[12]
6 Fricker S P. The therapeutic application of lanthanides. Chem Soc Rev, 2006, 35: 524–533？？
[13]
11 Bentley H, Hamdy F C, Hart K A, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer, 1992, 66: 1159–1163？？
[14]
12 Hamdy F C, Autzen P, Robinson M C, et al. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res, 1997, 57: 4427–4431
[15]
15 Brown J M, Corey E, Lee Z D, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology, 2001, 57: 611–616？？
